APO Research
Talk to an analyst

APO RESEARCH · REPORT

PEGylated Granulocyte-Colony Stimulating Factor

Compare research editions
View pricing & licenses

Selected research

Industry Research

PEGylated Granulocyte-Colony Stimulating Factor Industry Research Report 2026

28 December 2025121 pages

Choose your research edition.

Industry ResearchPEGylated Granulocyte-Colony Stimulating Factor Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal PEGylated Granulocyte-Colony Stimulating Factor Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal PEGylated Granulocyte-Colony Stimulating Factor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PEGylated Granulocyte-Colony Stimulating Factor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal PEGylated Granulocyte-Colony Stimulating Factor Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global PEGylated Granulocyte-Colony Stimulating Factor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for PEGylated Granulocyte-Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for PEGylated Granulocyte-Colony Stimulating Factor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for PEGylated Granulocyte-Colony Stimulating Factor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of PEGylated Granulocyte-Colony Stimulating Factor include Amgen, Coherus BioSciences, Fresenius Kabi, Kashiv BioSciences, Mylan, Pfizer, Sandoz, SL Pharm and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global PEGylated Granulocyte-Colony Stimulating Factor market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

PEGylated Granulocyte-Colony Stimulating Factor Market by Company

Amgen

Coherus BioSciences

Fresenius Kabi

Kashiv BioSciences

Mylan

Pfizer

Sandoz

SL Pharm

Jiangsu Hengrui Pharmaceuticals

Lunan Pharmaceutical

Qilu Pharmaceutical

Amoytop Biotech

CSPC Baike Biopharma

PEGylated Granulocyte-Colony Stimulating Factor Segment by Type

Telpegfilgrastim

Pegfilgrastim

Mecapegfilgrastim

Other

PEGylated Granulocyte-Colony Stimulating Factor Segment by Application

Hospital and Clinic

Pharmacy

Other

PEGylated Granulocyte-Colony Stimulating Factor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PEGylated Granulocyte-Colony Stimulating Factor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PEGylated Granulocyte-Colony Stimulating Factor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PEGylated Granulocyte-Colony Stimulating Factor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of PEGylated Granulocyte-Colony Stimulating Factor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of PEGylated Granulocyte-Colony Stimulating Factor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of PEGylated Granulocyte-Colony Stimulating Factor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global PEGylated Granulocyte-Colony Stimulating Factor Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units) of Manufacturers (2021-2026) Table 7. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Manufacturers (2021-2026) Table 8. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue of Manufacturers (2021-2026) Table 9. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Manufacturers (2021-2026) Table 10. Global Market PEGylated Granulocyte-Colony Stimulating Factor Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global PEGylated Granulocyte-Colony Stimulating Factor Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Product Type & Application Table 14. Global PEGylated Granulocyte-Colony Stimulating Factor Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global PEGylated Granulocyte-Colony Stimulating Factor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Amgen Company Information Table 19. Amgen Business Overview Table 20. Amgen PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Amgen PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 22. Amgen Recent Developments Table 23. Coherus BioSciences Company Information Table 24. Coherus BioSciences Business Overview Table 25. Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 27. Coherus BioSciences Recent Developments Table 28. Fresenius Kabi Company Information Table 29. Fresenius Kabi Business Overview Table 30. Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 32. Fresenius Kabi Recent Developments Table 33. Kashiv BioSciences Company Information Table 34. Kashiv BioSciences Business Overview Table 35. Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 37. Kashiv BioSciences Recent Developments Table 38. Mylan Company Information Table 39. Mylan Business Overview Table 40. Mylan PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Mylan PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 42. Mylan Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Pfizer PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 47. Pfizer Recent Developments Table 48. Sandoz Company Information Table 49. Sandoz Business Overview Table 50. Sandoz PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sandoz PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 52. Sandoz Recent Developments Table 53. SL Pharm Company Information Table 54. SL Pharm Business Overview Table 55. SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 57. SL Pharm Recent Developments Table 58. Jiangsu Hengrui Pharmaceuticals Company Information Table 59. Jiangsu Hengrui Pharmaceuticals Business Overview Table 60. Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 62. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 63. Lunan Pharmaceutical Company Information Table 64. Lunan Pharmaceutical Business Overview Table 65. Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 67. Lunan Pharmaceutical Recent Developments Table 68. Qilu Pharmaceutical Company Information Table 69. Qilu Pharmaceutical Business Overview Table 70. Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 72. Qilu Pharmaceutical Recent Developments Table 73. Amoytop Biotech Company Information Table 74. Amoytop Biotech Business Overview Table 75. Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 77. Amoytop Biotech Recent Developments Table 78. CSPC Baike Biopharma Company Information Table 79. CSPC Baike Biopharma Business Overview Table 80. CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 82. CSPC Baike Biopharma Recent Developments Table 83. Global PEGylated Granulocyte-Colony Stimulating Factor Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region (2021-2026) & (K Units) Table 85. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Region (2021-2026) Table 86. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region (2027-2032) & (K Units) Table 87. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Region (2027-2032) Table 88. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2021-2026) & (US$ Million) Table 89. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Region (2021-2026) Table 90. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2027-2032) & (US$ Million) Table 91. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Region (2027-2032) Table 92. North America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 94. North America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 95. North America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2021-2026) & (US$ Million) Table 96. North America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 99. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 100. Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 104. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 105. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2027-2032) & (US$ Million) Table 107. South America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 109. South America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 110. South America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2021-2026) & (US$ Million) Table 111. South America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 114. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 115. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2027-2032) & (US$ Million) Table 117. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2021-2026) & (K Units) Table 118. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2027-2032) & (K Units) Table 119. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2021-2026) Table 120. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2027-2032) Table 121. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2021-2026) & (US$ Million) Table 122. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2027-2032) & (US$ Million) Table 123. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2021-2026) Table 124. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2027-2032) Table 125. Global PEGylated Granulocyte-Colony Stimulating Factor Price by Type (2021-2026) & (US$/Unit) Table 126. Global PEGylated Granulocyte-Colony Stimulating Factor Price by Type (2027-2032) & (US$/Unit) Table 127. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2021-2026) & (K Units) Table 128. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2027-2032) & (K Units) Table 129. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2021-2026) Table 130. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2027-2032) Table 131. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2021-2026) & (US$ Million) Table 132. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2027-2032) & (US$ Million) Table 133. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2021-2026) Table 134. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2027-2032) Table 135. Global PEGylated Granulocyte-Colony Stimulating Factor Price by Application (2021-2026) & (US$/Unit) Table 136. Global PEGylated Granulocyte-Colony Stimulating Factor Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. PEGylated Granulocyte-Colony Stimulating Factor Distributors List Table 140. PEGylated Granulocyte-Colony Stimulating Factor Customers List Table 141. PEGylated Granulocyte-Colony Stimulating Factor Industry Trends Table 142. PEGylated Granulocyte-Colony Stimulating Factor Industry Drivers Table 143. PEGylated Granulocyte-Colony Stimulating Factor Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. PEGylated Granulocyte-Colony Stimulating Factor Product Image Figure 5. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global PEGylated Granulocyte-Colony Stimulating Factor Market Size (2021-2032) & (US$ Million) Figure 7. Global PEGylated Granulocyte-Colony Stimulating Factor Sales (2021-2032) & (K Units) Figure 8. Global PEGylated Granulocyte-Colony Stimulating Factor Average Price (US$/Unit) & (2021-2032) Figure 9. Telpegfilgrastim Product Image Figure 10. Pegfilgrastim Product Image Figure 11. Mecapegfilgrastim Product Image Figure 12. Other Product Image Figure 13. Hospital and Clinic Product Image Figure 14. Pharmacy Product Image Figure 15. Other Product Image Figure 16. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 PEGylated Granulocyte-Colony Stimulating Factor Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global PEGylated Granulocyte-Colony Stimulating Factor Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region in 2025 Figure 22. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region in 2025 Figure 23. North America PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country in 2025 Figure 24. North America PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 25. North America PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Country (2021-2032) Figure 26. United States PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country in 2025 Figure 30. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 31. Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Country (2021-2032) Figure 32. Germany PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country in 2025 Figure 43. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Country (2021-2032) Figure 45. China PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country in 2025 Figure 54. South America PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 55. South America PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Country (2021-2032) Figure 56. Brazil PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country in 2025 Figure 60. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Country (2021-2032) Figure 62. Egypt PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2021-2032) Figure 68. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2021-2032) Figure 69. Global PEGylated Granulocyte-Colony Stimulating Factor Price (US$/Unit) by Type (2021-2032) Figure 70. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2021-2032) Figure 71. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2021-2032) Figure 72. Global PEGylated Granulocyte-Colony Stimulating Factor Price (US$/Unit) by Application (2021-2032) Figure 73. PEGylated Granulocyte-Colony Stimulating Factor Value Chain Figure 74. PEGylated Granulocyte-Colony Stimulating Factor Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. PEGylated Granulocyte-Colony Stimulating Factor Industry Opportunities and Challenges

Scope & coverage.

Types
  • Telpegfilgrastim
  • Pegfilgrastim
  • Mecapegfilgrastim
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Amgen
  • Coherus BioSciences
  • Fresenius Kabi
  • Kashiv BioSciences
  • Mylan
  • Pfizer
  • Sandoz
  • SL Pharm
  • Jiangsu Hengrui Pharmaceuticals
  • Lunan Pharmaceutical
  • Qilu Pharmaceutical
  • Amoytop Biotech
  • CSPC Baike Biopharma

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Market Size (2021-2032)
  4. 2.2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales (2021-2032)
  5. 2.2.3 Global PEGylated Granulocyte-Colony Stimulating Factor Market Average Price (2021-2032)
  6. 2.3 PEGylated Granulocyte-Colony Stimulating Factor by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Telpegfilgrastim
  9. 2.3.3 Pegfilgrastim
  10. 2.3.4 Mecapegfilgrastim
  11. 2.3.5 Other
  12. 2.4 PEGylated Granulocyte-Colony Stimulating Factor by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Hospital and Clinic
  15. 2.4.3 Pharmacy
  16. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global PEGylated Granulocyte-Colony Stimulating Factor Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue of Manufacturers (2021-2026)
  4. 3.4 Global PEGylated Granulocyte-Colony Stimulating Factor Average Price by Manufacturers (2021-2026)
  5. 3.5 Global PEGylated Granulocyte-Colony Stimulating Factor Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Product Type & Application
  8. 3.8 Global Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Established Date
  9. 3.9 Global PEGylated Granulocyte-Colony Stimulating Factor Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Amgen
  2. 4.1.1 Amgen Company Information
  3. 4.1.2 Amgen Business Overview
  4. 4.1.3 Amgen PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Amgen PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  6. 4.1.5 Amgen Recent Developments
  7. 4.2 Coherus BioSciences
  8. 4.2.1 Coherus BioSciences Company Information
  9. 4.2.2 Coherus BioSciences Business Overview
  10. 4.2.3 Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  12. 4.2.5 Coherus BioSciences Recent Developments
  13. 4.3 Fresenius Kabi
  14. 4.3.1 Fresenius Kabi Company Information
  15. 4.3.2 Fresenius Kabi Business Overview
  16. 4.3.3 Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  18. 4.3.5 Fresenius Kabi Recent Developments
  19. 4.4 Kashiv BioSciences
  20. 4.4.1 Kashiv BioSciences Company Information
  21. 4.4.2 Kashiv BioSciences Business Overview
  22. 4.4.3 Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  24. 4.4.5 Kashiv BioSciences Recent Developments
  25. 4.5 Mylan
  26. 4.5.1 Mylan Company Information
  27. 4.5.2 Mylan Business Overview
  28. 4.5.3 Mylan PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Mylan PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  30. 4.5.5 Mylan Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 Sandoz
  38. 4.7.1 Sandoz Company Information
  39. 4.7.2 Sandoz Business Overview
  40. 4.7.3 Sandoz PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sandoz PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  42. 4.7.5 Sandoz Recent Developments
  43. 4.8 SL Pharm
  44. 4.8.1 SL Pharm Company Information
  45. 4.8.2 SL Pharm Business Overview
  46. 4.8.3 SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  48. 4.8.5 SL Pharm Recent Developments
  49. 4.9 Jiangsu Hengrui Pharmaceuticals
  50. 4.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 4.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 4.9.3 Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  54. 4.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 4.10 Lunan Pharmaceutical
  56. 4.10.1 Lunan Pharmaceutical Company Information
  57. 4.10.2 Lunan Pharmaceutical Business Overview
  58. 4.10.3 Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  60. 4.10.5 Lunan Pharmaceutical Recent Developments
  61. 4.11 Qilu Pharmaceutical
  62. 4.11.1 Qilu Pharmaceutical Company Information
  63. 4.11.2 Qilu Pharmaceutical Business Overview
  64. 4.11.3 Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  66. 4.11.5 Qilu Pharmaceutical Recent Developments
  67. 4.12 Amoytop Biotech
  68. 4.12.1 Amoytop Biotech Company Information
  69. 4.12.2 Amoytop Biotech Business Overview
  70. 4.12.3 Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  72. 4.12.5 Amoytop Biotech Recent Developments
  73. 4.13 CSPC Baike Biopharma
  74. 4.13.1 CSPC Baike Biopharma Company Information
  75. 4.13.2 CSPC Baike Biopharma Business Overview
  76. 4.13.3 CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  78. 4.13.5 CSPC Baike Biopharma Recent Developments
5 Global PEGylated Granulocyte-Colony Stimulating Factor Market Scenario by Region
  1. 5.1 Global PEGylated Granulocyte-Colony Stimulating Factor Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region: 2021-2032
  3. 5.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region: 2021-2026
  4. 5.2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region: 2027-2032
  5. 5.3 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region: 2021-2032
  6. 5.3.1 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region: 2021-2026
  7. 5.3.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region: 2027-2032
  8. 5.4 North America PEGylated Granulocyte-Colony Stimulating Factor Market Facts & Figures by Country
  9. 5.4.1 North America PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2032)
  11. 5.4.3 North America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe PEGylated Granulocyte-Colony Stimulating Factor Market Facts & Figures by Country
  16. 5.5.1 Europe PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2032)
  18. 5.5.3 Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America PEGylated Granulocyte-Colony Stimulating Factor Market Facts & Figures by Country
  41. 5.7.1 South America PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2032)
  43. 5.7.3 South America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2021-2032)
  2. 6.1.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2021-2032)
  4. 6.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2021-2032)
  5. 6.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2021-2032)
  7. 6.3 Global PEGylated Granulocyte-Colony Stimulating Factor Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2021-2032)
  2. 7.1.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2021-2032)
  4. 7.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2021-2032)
  5. 7.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2021-2032)
  7. 7.3 Global PEGylated Granulocyte-Colony Stimulating Factor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 PEGylated Granulocyte-Colony Stimulating Factor Value Chain Analysis
  2. 8.1.1 PEGylated Granulocyte-Colony Stimulating Factor Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 PEGylated Granulocyte-Colony Stimulating Factor Production Mode & Process
  5. 8.2 PEGylated Granulocyte-Colony Stimulating Factor Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 PEGylated Granulocyte-Colony Stimulating Factor Distributors
  8. 8.2.3 PEGylated Granulocyte-Colony Stimulating Factor Customers
9 Global PEGylated Granulocyte-Colony Stimulating Factor Analyzing Market Dynamics
  1. 9.1 PEGylated Granulocyte-Colony Stimulating Factor Industry Trends
  2. 9.2 PEGylated Granulocyte-Colony Stimulating Factor Industry Drivers
  3. 9.3 PEGylated Granulocyte-Colony Stimulating Factor Industry Opportunities and Challenges
  4. 9.4 PEGylated Granulocyte-Colony Stimulating Factor Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst